The Adrenal Crosstalk: Examining the Mechanisms of Cortisol-Driven Oestrogen Dominance

Overview

The phenomenon of "Adrenal Crosstalk" represents a critical, often overlooked frontier in endocrinology, where the chronic activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis fundamentally reconfigures the Hypothalamic-Pituitary-Gonadal (HPG) axis. At INNERSTANDIN, we move beyond the simplistic narrative of "stress" to expose the precise molecular mechanisms by which hypercortisolemia precipitates a state of functional oestrogen dominance. This is not merely a hormonal imbalance; it is a systemic metabolic hijacking that compromises cellular integrity and homeostatic resilience.

The primary driver of this crosstalk is the biochemical prioritisation of survival over reproduction, mediated by enzymatic competition within the steroidogenic pathways of the adrenal cortex. Under conditions of prolonged physiological or psychological distress, the demand for cortisol leads to what is colloquially termed the "pregnenolone steal" or, more accurately, the diversion of the precursor pregnenolone away from the synthesis of progesterone and towards the production of glucocorticoids. This enzymatic shunt is facilitated by the upregulation of 3β-hydroxysteroid dehydrogenase and 11β-hydroxylase. Consequently, the depletion of progesterone—an essential oestrogen antagonist and modulator—leaves the oestrogen receptors (ERα and ERβ) unopposed, effectively creating a state of oestrogen dominance even when absolute oestrogen levels remain within "normal" clinical ranges.

Furthermore, research published in journals such as *The Lancet Diabetes & Endocrinology* and *The Journal of Clinical Endocrinology & Metabolism* highlights that cortisol directly upregulates the CYP19A1 gene. This gene encodes the aromatase enzyme, primarily in peripheral adipose tissue and the mammary glands. Increased aromatase activity accelerates the conversion of androstenedione and testosterone into oestrone (E1) and oestradiol (E2), respectively. This creates a vicious cycle: chronic cortisol elevation increases visceral adiposity, which in turn provides more substrate for aromatase, further intensifying the hyperoestrogenic state.

From a UK clinical perspective, the systemic impacts are profound. Cortisol also exerts a suppressive effect on Sex Hormone-Binding Globulin (SHBG) synthesis in the liver. A reduction in SHBG increases the bioavailability of "free" oestradiol, allowing it to exert disproportionate genomic effects on target tissues, including the endometrium and breast tissue. Moreover, high levels of Corticotropin-Releasing Hormone (CRH) have been shown to inhibit the release of Gonadotropin-Releasing Hormone (GnRH), leading to luteal phase defects and anovulation, which further exacerbates the oestrogen-to-progesterone ratio. At INNERSTANDIN, we define this interplay as a molecular siege, where the body's emergency response system inadvertently dismantles the delicate equilibrium of the reproductive endocrine environment, necessitating a sophisticated, multi-layered approach to biological restoration.

The Biology — How It Works

The biochemical nexus between the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis represents a sophisticated survival mechanism that, under the chronic pressures of modern British life, becomes the primary driver of functional oestrogen dominance. At the heart of this "Crosstalk" is the steroidogenic priority system. Within the mitochondria of the adrenal cortex, the conversion of cholesterol into pregnenolone by the enzyme cytochrome P450scc serves as the "master switch" for all steroid hormones. However, under conditions of perceived environmental or physiological threat—hypercortisolaemia—the body prioritises the production of cortisol over progestogens. This phenomenon, often termed the "pregnenolone steal" or progesterone-cortisol shunt, creates a systemic deficit in progesterone, the primary antagonist to oestrogen’s proliferative effects.

The molecular reality is rooted in the competitive inhibition of enzymes. When the HPA axis is chronically up-regulated, the activity of 3β-hydroxysteroid dehydrogenase and various hydroxylases is diverted toward the fasciculata zone of the adrenal glands. This not only depletes the precursor pool for progesterone synthesis in the corpus luteum but also disrupts the pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus. Research published in *The Journal of Clinical Endocrinology & Metabolism* confirms that elevated glucocorticoids suppress the sensitivity of pituitary gonadotropes to GnRH, effectively blunting the Luteinising Hormone (LH) surge required for ovulation. Without a robust LH surge, the follicle fails to rupture or forms a weak corpus luteum, leading to sub-optimal progesterone levels that cannot counterbalance circulating oestradiol.

Furthermore, cortisol directly modulates the peripheral synthesis of oestrogen through the upregulation of the *CYP19A1* gene, which encodes the aromatase enzyme. In the adipose tissue and stromal cells of the breast and endometrium, cortisol acts as a potent stimulus for aromatase activity, accelerating the conversion of adrenal androgens (androstenedione) into oestrone (E1). This creates a paracrine feedback loop where stress-induced inflammation further sensitises oestrogen receptors (ERα), particularly in the presence of low-grade systemic inflammation prevalent in UK clinical cohorts.

The systemic impact extends to hepatic clearance. For the body to maintain oestrogen homeostasis, the liver must efficiently process oestradiol through Phase I (hydroxylation) and Phase II (conjugation) pathways. Chronic cortisol elevation induces oxidative stress that impairs the Catechol-O-methyltransferase (COMT) enzyme and glucuronidation pathways. When these pathways are congested, oestrogen is not excreted; instead, it is deconjugated in the gut by beta-glucuronidase—often elevated in dysbiotic states—and reabsorbed into systemic circulation. This "enterohepatic recirculation" compounds the oestrogenic load. At INNERSTANDIN, we recognise that oestrogen dominance is rarely an isolated glandular failure; it is a predictable downstream consequence of adrenal-driven metabolic diversion, where the biological imperative for survival over-rides the requirements for reproductive equilibrium. This creates a state of "functional dominance" where, even if absolute oestrogen levels appear within a standard British reference range, the lack of progesterone opposition and impaired metabolic clearance result in a state of cellular oestrogenic toxicity.

Mechanisms at the Cellular Level

To elucidate the cellular underpinning of cortisol-driven oestrogen dominance, one must first confront the biochemical triage occurring within the steroidogenic pathways of the adrenal cortex and the peripheral tissues. At the heart of this "Adrenal Crosstalk" lies the competitive utilisation of pregnenolone, the "mother hormone." Under conditions of chronic hypothalamic-pituitary-adrenal (HPA) axis activation—a pervasive state in the modern UK landscape—the biosynthetic flux is aggressively diverted toward cortisol production to meet the perceived physiological demand. This phenomenon, often termed the "pregnenolone steal" in clinical endocrinology, results in a quantifiable deficit in the precursor pool available for dehydroepiandrosterone (DHEA) and progesterone synthesis. At the cellular level, this creates a state of relative oestrogen dominance, not necessarily through an absolute increase in oestradiol, but through the catastrophic withdrawal of its primary physiological antagonist: progesterone.

However, the mechanism extends far beyond mere precursor diversion. Research indexed in *The Lancet* and various PubMed-archived studies highlight the role of cortisol as a potent modulator of aromatase (CYP19A1) activity. In peripheral adipocytes and breast tissue, glucocorticoids synergise with inflammatory cytokines (such as IL-6 and TNF-α) to upregulate the expression of the *CYP19A1* gene. This enzymatic hijacking accelerates the conversion of androstenedione into oestrone (E1) and testosterone into oestradiol (E2). Consequently, the hypercortisolaemic state actively fuels the peripheral production of oestrogens, creating a self-sustaining feedback loop of hormonal disproportion.

Furthermore, the crosstalk manifests at the level of nuclear receptor sensitivity. Cortisol and progesterone share a high degree of structural homology, allowing cortisol to exhibit significant affinity for the progesterone receptor (PR). When cortisol levels are chronically elevated, it may act as a competitive antagonist at the PR, effectively "blocking" the calming and anti-proliferative signals of progesterone even when serum levels of the hormone appear within the reference range. This receptor-level interference is a critical component of the INNERSTANDIN pedagogical framework, as it explains why symptomatic oestrogen dominance frequently persists despite "normal" clinical labs.

The systemic impact is further compounded by cortisol’s influence on hepatic Sex Hormone-Binding Globulin (SHBG) synthesis. Prolonged glucocorticoid elevation, particularly when coupled with the hyperinsulinaemia seen in metabolic distress, suppresses hepatic SHBG production. This reduces the buffering capacity of the blood, increasing the fraction of "free" or bioactive oestradiol. Finally, the metabolic clearance of oestrogen is compromised; cortisol competes for the same Phase I cytochrome P450 enzymes and Phase II conjugation pathways (notably glucuronidation and methylation) required for oestrogen detoxification. By saturating these hepatic pathways, cortisol ensures that oestrogen metabolites—specifically the more proliferative 16α-hydroxyestrone—circulate for longer durations, exerting prolonged genomic effects on sensitive tissues. This intricate cellular orchestration reveals that oestrogen dominance is not a primary gonadal failure, but a secondary consequence of an over-burdened adrenal system.

Environmental Threats and Biological Disruptors

The contemporary landscape of the United Kingdom presents a unique biological challenge, where the convergence of chronic psychological stress and ubiquitous chemical exposure orchestrates a profound disruption of the endocrine architecture. At the heart of this disruption lies the synergistic relationship between exogenous endocrine-disrupting chemicals (EDCs) and the endogenous dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Within the INNERSTANDIN framework, we must scrutinise how these external threats do not merely coexist with biological systems but actively hijack the steroidogenic pathways, specifically driving the phenomenon of oestrogen dominance through adrenal mediation.

Primary amongst these environmental threats are xenoestrogens—synthetic compounds such as bisphenol A (BPA), phthalates, and polychlorinated biphenyls (PCBs)—which remain prevalent in UK water systems and consumer goods despite evolving regulations. These compounds possess a high affinity for oestrogen receptors (ERα and ERβ), where they act as potent agonists, mimicking the molecular structure of 17β-oestradiol. However, their impact is magnified by the concurrent state of hypercortisolaemia. Research published in *The Lancet Diabetes & Endocrinology* underscores that chronic cortisol elevation, a hallmark of the modern UK 'stress-economy,' serves as a primary driver for the upregulation of the CYP19A1 gene. This gene encodes the aromatase enzyme, which facilitates the peripheral conversion of androgens into oestrogens, particularly in adipose tissue. Thus, environmental stress acts as a biochemical catalyst, transforming the body’s own steroid precursors into an oestrogenic surplus.

Furthermore, the biological disruptors found in modern pesticides—frequently detected in UK-grown produce—interfere with the hepatic clearance of these excess hormones. The liver’s Phase II detoxification pathways, specifically glucuronidation and methylation, are often saturated by the high toxic load of organochlorines and heavy metals. When the liver is preoccupied with neutralising these xenobiotics, its capacity to metabolise and excrete oestrogen metabolites (such as 2-hydroxyoestrone or 16α-hydroxyoestrone) is severely compromised. This leads to the enterohepatic recirculation of deconjugated oestrogens, further elevating systemic levels.

INNERSTANDIN analysis reveals that this is not a linear pathology but a feedback loop; high oestrogen levels sensitise the HPA axis to further stress, while the resultant cortisol spike continues to inhibit the production of progesterone—the natural antagonist to oestrogen—by prioritising the 'pregnenolone steal' for glucocorticoid synthesis. Peer-reviewed data from PubMed indicates that this crosstalk is further exacerbated by the reduction of Sex Hormone-Binding Globulin (SHBG) in the presence of environmental toxins and insulin resistance. With lower SHBG levels, the fraction of 'free,' biologically active oestrogen increases, cementing a state of dominance that is both environmentally induced and adrenally sustained. This systemic failure represents a critical intersection where environmental toxicology meets maladaptive endocrinology, requiring an exhaustive understanding of the molecular interplay to rectify.

The Cascade: From Exposure to Disease

The physiological descent into cortisol-mediated oestrogen dominance is initiated by a systemic erosion of the homeostatic balance between the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-gonadal (HPG) axes. At the heart of this cascade lies the "pregnenolone steal" (or progestogen shunt), a phenomenon where chronic psychogenic or physiological stressors compel the adrenal cortex to prioritise the synthesis of glucocorticoids over gonadal precursors. Within the mitochondria of the zona fasciculata, the enzymatic conversion of cholesterol to pregnenolone by the side-chain cleavage enzyme (CYP11A1) becomes the rate-limiting bottleneck. Under the relentless stimulus of adrenocorticotropic hormone (ACTH), the majority of available pregnenolone is diverted toward the 17-hydroxypregnenolone and 11-deoxycortisol pathway. This bypasses the synthesis of progesterone, leading to a precipitous decline in its serum concentrations and a subsequent loss of its crucial antagonistic effect on oestrogen receptors (ERs).

As progesterone levels plummet, the oestrogen-to-progesterone ratio shifts toward a pathological dominance, even in instances where absolute oestradiol levels remain within the "reference range" cited by conventional UK pathology labs. However, the cascade intensifies through the peripheral induction of aromatase (CYP19A1). Elevated systemic cortisol, particularly when coupled with the pro-inflammatory cytokines IL-6 and TNF-alpha, acts as a potent stimulator of aromatase expression within the stromal vascular fraction of white adipose tissue. This results in the accelerated peripheral conversion of androgens into oestrone (E1) and oestradiol (E2). Research indexed in *The Lancet Diabetes & Endocrinology* highlights that this feed-forward loop is exacerbated in the context of insulin resistance, a prevalent metabolic phenotype in the UK.

Furthermore, the bioavailable fraction of oestrogen is heightened by cortisol’s suppressive effect on hepatic Sex Hormone-Binding Globulin (SHBG) synthesis. By inhibiting the liver’s production of these transport proteins, cortisol increases the concentration of free, unbound oestradiol, which is then capable of diffusing into target tissues—breast, endometrium, and prostate—where it exerts potent proliferative signals. This molecular environment is further compromised by the impairment of Phase I and Phase II detoxification pathways. Under hypercortisolaemic conditions, the cytochrome P450 1A1 pathway is often outcompeted by the 1B1 pathway, favouring the production of 16α-hydroxyoestrone over the safer 2-hydroxyoestrone metabolite.

The culmination of this cascade is not merely a hormonal imbalance but a state of genomic instability. The persistence of 4-hydroxy and 16α-hydroxy metabolites leads to the formation of DNA adducts, as established in numerous PubMed-referenced oncology studies, providing the mechanistic link between chronic HPA-axis dysregulation and the rising UK incidence of oestrogen-sensitive neoplasms and endometriosis. At INNERSTANDIN, we recognise that this is not a random malfunction but a predictable biological consequence of sustained adrenal overload, where the body's survival mechanisms inadvertently fuel a landscape of cellular proliferation and systemic disease.

What the Mainstream Narrative Omits

The reductionist paradigm prevalent within contemporary clinical practice frequently isolates the endocrine system into disparate silos, treating adrenal dysfunction and sex-steroid imbalances as unrelated pathologies. At INNERSTANDIN, we contend that this diagnostic myopia overlooks the profound biochemical synthesis known as the "Pregnenolone Steal"—or more accurately, the metabolic prioritisation of the glucocorticoid pathway at the expense of C19 and C18 steroidogenesis. While mainstream narratives focus almost exclusively on exogenous xenoestrogens, they omit the critical role of the hypothalamic-pituitary-adrenal (HPA) axis in modulating endogenous oestrogen bioavailability through hepatic and enzymatic interference.

Central to this omission is the role of Sex Hormone-Binding Globulin (SHBG). Chronic hypercortisolaemia, a hallmark of the modern UK high-stress environment, significantly suppresses hepatic synthesis of SHBG. Research published in the *Journal of Clinical Endocrinology & Metabolism* demonstrates that as SHBG levels plummet, the "free" or unbound fraction of oestradiol (E2) increases. Consequently, a patient may present with "normal" total oestrogen levels on a standard NHS serum test, yet suffer from systemic oestrogen dominance at the cellular level due to an elevated free hormone index. This is a crucial distinction that the conventional "reference range" model fails to capture.

Furthermore, the mainstream narrative ignores the cortisol-mediated upregulation of the *CYP19A1* gene, which encodes the aromatase enzyme. Cortisol, particularly when acting synergistically with pro-inflammatory cytokines like IL-6 and TNF-α, stimulates aromatase activity within white adipose tissue. This creates a feed-forward loop where stress-induced cortisol directly accelerates the peripheral conversion of androstenedione into oestrone (E1). This enzymatic "crosstalk" ensures that even in the absence of ovarian output, the body remains in a hyper-oestrogenic state, driven by adrenal demand.

Crucially, the molecular competition for the Progesterone Receptor (PR) is rarely discussed outside of advanced endocrinology. Cortisol possesses a structural homology with progesterone; under conditions of chronic stress, high-titre cortisol can competitively inhibit progesterone binding or downregulate PR sensitivity. This results in "functional" oestrogen dominance, where oestrogen's proliferative effects go unopposed not because progesterone is absent, but because its signalling pathways are physically obstructed by glucocorticoid dominance. By failing to account for these ligand-receptor dynamics and the hepatic clearance bottlenecks induced by HPA-axis overactivity, mainstream protocols remain ineffective at addressing the root metabolic drivers of hormonal dysregulation. Only by examining the steroidogenic flux through the lens of adrenal prioritisation can we truly decipher the mechanisms of systemic oestrogen dominance.

The UK Context

In the contemporary British landscape, the phenomenon of ‘Burnout Britain’ is not merely a sociological observation but a physiological crisis manifesting through the dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Within the UK population, the prevalence of chronic psychosocial stressors—ranging from the cost-of-living crisis to the highest commuting times in Europe—has created a state of systemic hypercortisolaemia. Research indexed in the *Lancet* and data from the UK Biobank suggest a direct correlation between urbanised stress and the disruption of the Hypothalamic-Pituitary-Gonadal (HPG) axis, providing a fertile ground for oestrogen dominance. At INNERSTANDIN, we identify this as a failure of ‘Adrenal Crosstalk,’ where the metabolic priority of survival (cortisol production) overruns the requirement for reproductive equilibrium.

The primary biochemical mechanism at play is the ‘Pregnenolone Steal’ or, more accurately, the redirection of steroidogenic flux. Under the sustained demand for cortisol, the adrenal cortex sequester progesterone precursors, such as pregnenolone, to satisfy the glucocorticoid pathway. In the British clinical context, this results in a precipitous decline in luteal-phase progesterone, leading to a state of relative oestrogen dominance even if absolute oestradiol levels remain within reference ranges. Furthermore, the UK’s rising obesity rates—with NHS Digital reporting that 28% of adults are living with obesity—exacerbate this crosstalk. Cortisol facilitates the deposition of visceral adipose tissue, which expresses high levels of the enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). This enzyme locally regenerates active cortisol from cortisone, creating a self-sustaining loop of adrenal-driven adiposity. This visceral fat then acts as an endocrine organ, secreting the aromatase enzyme (CYP19A1), which peripherally converts androstenedione into oestrone (E1), further tipping the hormonal scales.

The UK context

is uniquely complicated by environmental xenoestrogens. Studies on British water systems have frequently identified residues of ethinylestradiol and other endocrine-disrupting chemicals (EDCs) that survive wastewater treatment. When these external oestrogens meet an internal environment already primed by cortisol-induced progesterone depletion, the result is a synergistic exacerbation of oestrogen-sensitive pathologies, including endometriosis and fibroids. At INNERSTANDIN, our research highlights that the HPA-HPG crosstalk is not a series of isolated events but a systemic failure of homoeostasis. The suppression of Gonadotropin-Releasing Hormone (GnRH) by high cortisol levels inhibits the surge of Luteinising Hormone (LH), often resulting in anovulatory cycles. Without the corpus luteum to produce progesterone, oestrogen remains unopposed, cementing a state of physiological dominance that is reflective of the modern British biological condition. To address this, one must move beyond symptomatic suppression and deconstruct the adrenal-driven metabolic shunting that defines this epidemic.

Protective Measures and Recovery Protocols

To ameliorate the systemic fallout of the cortisol-oestrogen nexus, clinical intervention must transcend symptomatic suppression, focusing instead on the recalibration of the hypothalamic-pituitary-adrenal-gonadal (HPAG) axis and the restoration of hepatic biotransformation pathways. At the vanguard of INNERSTANDIN research is the modulation of the steroidal flux, specifically targeting the redirection of pregnenolone. Chronic hypercortisolaemia initiates a "metabolic shunt" wherein the steroidal precursor pregnenolone is prioritised for glucocorticoid synthesis at the expense of progesterone. Recovery protocols must prioritising the restoration of the progesterone-to-oestrogen ratio by reducing ACTH-driven adrenal demand. High-affinity ligands such as phosphatidylserine have demonstrated significant efficacy in blunting the ACTH and cortisol response to physical and psychological stressors, thereby preserving the progestogenic pool required to antagonise oestrogen’s proliferative effects at the cellular level.

From a biochemical standpoint, the upregulation of the *CYP19A1* gene (aromatase) by cortisol represents a primary driver of endogenous oestrogen production in peripheral tissues. To counter this, the implementation of specific polyphenolic compounds, such as chrysin and apigenin, is essential. These act as competitive inhibitors of the aromatase enzyme, mitigating the conversion of androstenedione into oestrone (E1). Furthermore, the hepatic clearance of oestrogen metabolites—specifically the ratio of 2-hydroxyestrone (2-OH) to 16α-hydroxyestrone (16-OH)—is frequently compromised under adrenal duress. Research published in the *British Journal of Cancer* underscores the necessity of inducing the CYP1A1 pathway to favour the "protective" 2-OH metabolite. Sulforaphane and Indole-3-Carbinol (I3C) serve as potent agonists of the aryl hydrocarbon receptor (AhR), which upregulates Phase I hydroxylation towards the 2-OH pathway, effectively reducing the systemic oestrogenic load.

In the UK context, where environmental xenoestrogen exposure is a significant confounding variable, the integrity of Phase II conjugation—specifically glucuronidation—is paramount. Cortisol-induced oxidative stress often depletes the glutathione pool and inhibits the enzyme UDP-glucuronosyltransferase (UGT). Recovery protocols must incorporate Calcium D-Glucarate, which inhibits the bacterial enzyme beta-glucuronidase in the gut microbiome (the oestrobolome). By preventing the de-conjugation and subsequent reabsorption of oestrogens into the enterohepatic circulation, Calcium D-Glucarate ensures the definitive excretion of these metabolites.

Furthermore, the recovery of the 11β-Hydroxysteroid Dehydrogenase (11β-HSD) system is a critical, yet often overlooked, mechanism. Type 1 11β-HSD facilitates the conversion of inactive cortisone to active cortisol; in states of oestrogen dominance, this enzyme is frequently overexpressed in adipose tissue, creating a feedback loop of adiposity and hormonal dysregulation. The introduction of glycyrrhetinic acid-free botanical modulators and magnesium threonate—which supports over 300 enzymatic reactions including those governing the ATP-dependent sequestration of oestrogen receptors—is vital for breaking this cycle. This exhaustive approach to HPAG recalibration ensures that the INNERSTANDIN framework for hormonal recovery is grounded in the hard-science of molecular biology and endocrine synchrony.

Summary: Key Takeaways

The biochemical nexus between hypothalamic-pituitary-adrenal (HPA) axis dysregulation and oestrogen dominance represents a critical frontier in endocrine research. Central to this crosstalk is the "pregnenolone steal" (or progesterone escape) phenomenon, whereby the acute and chronic demand for glucocorticoid production prioritises cortisol synthesis over progestogen precursors. This diversion, validated in numerous PubMed-indexed longitudinal studies, creates a relative deficiency in progesterone, thereby stripping the body of its primary physiological oestrogen antagonist. Furthermore, hypercortisolaemia induces a significant up-regulation of the CYP19A1 gene, particularly within peripheral adipose tissues. This enzymatic induction accelerates the aromatization of androstenedione into oestrone, compounding the systemic oestrogenic load through non-gonadal pathways.

Research within the UK clinical landscape further indicates that elevated cortisol levels significantly impair hepatic phase II detoxification pathways—specifically glucuronidation and sulphation—effectively delaying the metabolic clearance of catechol oestrogens. This retention exacerbates the proliferative signalling of oestradiol at the nuclear receptor level. At INNERSTANDIN, our analysis underscores that this is not merely an isolated hormonal imbalance but a systemic metabolic redirection. The synergistic impact of cortisol-driven aromatase activity and impaired biliary excretion creates a pro-inflammatory feedback loop that recalibrates the HPG axis toward a state of chronic oestrogen dominance. This evidence-led perspective reveals that resolving oestrogenic pathology necessitates the prior stabilisation of adrenal kinetics to restore homeostatic steroidogenesis and ensure the integrity of the endocrine system.